CorMedix Boosts 2026 Guidance After Strong Q1, REZZAYO Trial Success
Event summary
- CorMedix reported Q1 2026 net revenue of $127.4M, up from $39.1M in Q1 2025, driven by DefenCath sales and the Melinta acquisition.
- Net income reached $38.6M, with adjusted EBITDA at $70.0M, leading to raised FY 2026 guidance.
- REZZAYO Phase III trial results were positive, with FDA submission expected in H2 2026.
- DefenCath sales contributed $97.5M, including a $9.0M non-recurring change in sales allowances.
The big picture
CorMedix's strong Q1 2026 performance reflects the integration of the Melinta acquisition and robust demand for DefenCath. The positive REZZAYO trial results position the company for potential revenue expansion, though regulatory hurdles and post-TDAPA sales trends remain critical. The biopharmaceutical sector continues to favor companies with diversified portfolios and late-stage pipeline assets, aligning with CorMedix's strategic focus on institutional healthcare settings.
What we're watching
- Regulatory Timeline
- Whether CorMedix can secure FDA approval for REZZAYO's expanded indication by 2027.
- Revenue Sustainability
- How DefenCath sales will perform post-TDAPA expiration without the non-recurring $9.0M adjustment.
- Pipeline Progress
- The pace at which CorMedix accelerates enrollment for its taurolidine/heparin catheter lock solution study.
Our editorial coverage:
Related topics